Questcor Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc. (Questcor Pharma) is a publicly held bio pharmaceutical company. It is specialized in the provision of prescription drugs for treating rare central nervous system and inflammatory disorders. The product portfolio of the company include H.P acthar gel (repository corticotropin hormone) is a naturally-derived formulation of adrenocorticotropic hormones for use in various disorders having an inflammatory component; and doral used for the treatment of insomnia. It is also involved in developing new drugs, such as QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen used to treat moderate to moderately pain in patients with swallowing difficulties. The company was formed as a result of merger of Cypros Pharmaceutical Corporation and RiboGene Inc. Questcor Pharma is headquartered in California, the US.The company reported revenues of (U.S. Dollars) USD 95.25 million during the fiscal year ended December 2008, an increase of 91.38% over 2007. The operating profit of the company was USD 57.58 million during the fiscal year 2008, an increase of 167.13% over 2007. The net profit of the company was USD 40.53 million during the fiscal year 2008, an increase of 7.84% over 2007.